| Schedule of financial information regularly reviewed and used by the CODM |
This decision making process reflects the way in which the financial information is regularly reviewed and used by the CODM to evaluate performance, set operational targets, forecast future financial results, and allocate resources.
|
|
|
|
|
|
|
|
|
Three months ended March 31, |
|
|
2025 |
|
|
2024 |
|
Costs and expenses: |
|
|
|
|
|
Research and development (excluding share-based compensation) expense: |
|
|
|
|
|
PAH |
$ |
9,330,844 |
|
|
$ |
— |
|
Parkinson's disease |
|
142,420 |
|
|
|
2,343,896 |
|
Other programs |
|
587,128 |
|
|
|
389,453 |
|
Selling, general and administrative (excluding share-based compensation) |
|
3,660,282 |
|
|
|
1,995,577 |
|
Change in fair value contingent consideration |
|
(1,164,864 |
) |
|
|
— |
|
Share-based compensation expense |
|
2,042,196 |
|
|
|
53,434 |
|
Total costs and expenses |
|
14,598,006 |
|
|
|
4,782,360 |
|
Loss from operations |
|
(14,598,006 |
) |
|
|
(4,782,360 |
) |
Interest income |
|
919,271 |
|
|
|
132,725 |
|
Net loss |
$ |
(13,678,735 |
) |
|
$ |
(4,649,635 |
) |
|